Category
Industry
Companies
Contracts
Publication Contract Clauses (150)
Grouped Into 4 Collections of Similar Clauses From Business Contracts
This page contains Publication clauses in business contracts and legal agreements. We have organized these clauses into groups of similarly worded clauses.
Publication. 13.1.Publicity. Unless otherwise required by Applicable Law (including regulations under any stock exchange on which either Party or its Affiliates is listed), neither Party shall make any public announcement concerning this Agreement or any Study (including any postings to www.clinicaltrials.gov. under Section 13.2) or otherwise communicate with any news media without the prior written consent of the other Party. Without limiting the previous sentence, to the extent a Party desires to make such... public announcement, such Party shall provide the other Party with a draft thereof at least seven (7) Business Days prior to the date on which such Party would like to make the public announcement, unless such ten day prior notice is not possible in order to comply with Applicable Laws (including regulations under any stock exchange on which either Party or its Affiliates is listed); further provided however, that, in such case such Party shall provide the other Party with as much advance notice as reasonably practicable. 13.2.Registration. Sponsor will register each Study with the Clinical Trials Registry located at www.clinicaltrials.gov as required by Applicable Law. 24 13.3.Publications. Sponsor shall have the first right to publish Study Results subject to Section 13.4 and shall use commercially reasonable efforts to publish or present scientific papers regarding the Study Plan and Study Results in accordance with accepted scientific practice. Regeneron agrees not to publish Study Results for any Study prior to the timely publication of the Study Results from such Study by Sponsor. 13.4.Review. The Parties agree that prior to submission of any Study Data for publication or presentation or any other dissemination of any such results, including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to be published or presented according to the following procedure: (i)At least forty-five (45) days prior to submission for publication of any paper, letter or any other publication, or thirty (30) days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party the full details of the proposed publication or presentation in an electronic version (cd rom or email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation for an additional sixty (60) days in order to allow for actions to be taken to preserve rights for patent protection. (ii)The publishing Party shall give reasonable consideration to any request by the other Party made within the periods mentioned in clause (i) of this Section 13.4 to modify the publication. (iii)The publishing Party shall remove all Confidential Information of the other Party (but shall not remove jointly owned Study Data) before finalizing the publication. 13.5.Acknowledgement. Each Party agrees to identify the other Party and acknowledge its support in any press release and any other publication or presentation of the results of any Study.
View More
View Variations (3)
Found in
MAIA Biotechnology, Inc. contract
Publication. 13.1.Publicity. Unless otherwise required by Applicable Law (including regulations under any stock exchange on which either Party or its Affiliates is listed), neither Party shall make any public announcement concerning this Agreement or any Study (including any postings to www.clinicaltrials.gov. under Section 13.2) or otherwise communicate with any news media without the prior written consent of the other Party. Without limiting the previous sentence, to the extent a Party desires to make such... public announcement, such Party shall provide the other Party with a draft thereof at least seven (7) Business Days prior to the date on which such Party would like to make the public announcement, unless such ten day prior notice is not possible in order to comply with Applicable Laws (including regulations under any stock exchange on which either Party or its Affiliates is listed); further provided however, that, in such case such Party shall provide the other Party with as much advance notice as reasonably practicable. 13.2.Registration. Sponsor 17.1GSK will register each Study the Sub-Study with the Clinical Trials Registry located at www.clinicaltrials.gov as required by Applicable Law. 24 13.3.Publications. Sponsor shall have and is committed to timely publication of the first right results following Sub-Study Completion, after taking appropriate action to publish Study Results subject to Section 13.4 and secure Intellectual Property Rights (if any, in accordance with Article 16) arising from the Sub-Study. The publication of the results of the Sub-Study will be in accordance with the Sub-Study Protocol. [***]. 17.2GSK shall use commercially reasonable efforts to publish or present scientific papers regarding dealing with the Study Plan and Study Results Sub-Study in accordance with accepted scientific practice. Regeneron agrees not to publish Study Results for any Study prior to the timely publication of the Study Results from such Study by Sponsor. 13.4.Review. The 17.3The Parties agree that prior to submission of any Study Data the results of the Sub-Study for publication or presentation or any other dissemination of any such results, results including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to be published or presented according to the following procedure: (i)At (a)At least forty-five (45) [***] days prior to submission for publication of any paper, letter or any other publication, or thirty (30) days [***]days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party the full details of the proposed publication or presentation in an electronic version (cd rom (CD-ROMs or email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation for an additional sixty (60) [***] days in order to allow for actions to be taken to preserve rights for patent protection. (ii)The (b)The publishing Party shall give reasonable consideration to any request by the other Party made within the periods mentioned in clause (i) of this Section 13.4 (a) above to modify the publication. (iii)The [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. (c)The publishing Party shall remove all Confidential Information requested by the other Party before finalizing the publication. (d)In the event of a disagreement as to content, timing and/or venue or forum for any disclosure, publication or presentation of the Sub-Study results, such dispute shall be referred to the Project Managers (or their respective designees) to be resolved by way of good faith discussions for a period of [***] days following such referral; provided that, the publishing Party may proceed with the disclosure, publication or presentation provided that such disclosure, publication or presentation is consistent with its internal publication guidelines and customary industry practices for the publication of similar data and does not disclose the Confidential Information of the other Party (but (other than the Licensed Clinical Data). Authorship of any publication shall be determined based on the accepted standards used in peer-reviewed academic journals at the time of the proposed disclosure, publication or presentation. (e)SpringWorks shall not remove jointly owned Study Data) before finalizing publish, for any purpose, the publication. 13.5.Acknowledgement. Each results of the Sub-Study without the prior written approval of GSK, which approval shall be obtained in accordance with the procedure set forth in Sections 17.3(a) through 17.3(c) and shall not be unreasonably withheld. 17.4SpringWorks may issue a press release in the form attached hereto as Appendix C provided, however, that SpringWorks shall notify [***] Business Days in advance of such press release. 17.5Each Party agrees to identify the other Party and acknowledge its the other Party's support and contributions in any permitted press release and any other permitted publication or presentation of the results of any Study. the Sub-Study.
View More
Publication. 13.1.Publicity. 12.1 Publicity. Unless otherwise required by Applicable Law (including regulations under any stock exchange on which either Party or its Affiliates is listed), other than the agreed press release set forth on Appendix C hereto, neither Party shall make any public announcement concerning this Agreement or any Study that includes Regeneron Product (including any postings the initial posting to www.clinicaltrials.gov. under Section 13.2) www.clinicaltrials.gov.) or otherwise communi...cate with any news media without the prior written 27 Regeneron - Confidential consent of the other Party. Without limiting the previous sentence, to the extent a Party desires to make such public announcement, announcement beyond that set forth on Appendix C hereto, such Party shall provide the other Party with a draft thereof at least seven (7) ten (10) Business Days prior to the date on which such Party would like to make the public announcement, unless such ten day prior notice is not possible in order to comply with Applicable Laws (including regulations under any stock exchange on which either Party or its Affiliates is listed); further provided however, that, in such case such Party shall provide the other Party with as much advance notice as reasonably practicable. 13.2.Registration. 12.2 Registration. Sponsor will register each Study with the Clinical Trials Registry located at www.clinicaltrials.gov as required by Applicable Law. 24 13.3.Publications. 12.3 Publications. Sponsor shall have the first right to publish Study Data and Study Results subject to Section 13.4 and shall use commercially reasonable efforts to publish or present scientific papers regarding the Study Plan and Study Results in accordance with accepted scientific practice. Regeneron agrees not to publish Study Data or Study Results for any Study prior to the timely publication of the Study Data and/or Study Results from such Study by Sponsor. 13.4.Review. 12.4 Review. The Parties agree that prior to submission of any Study Data or Study Results for publication or presentation or any other dissemination of any such results, including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to be published or presented according to the following procedure: (i)At (i) At least forty-five (45) thirty (30) days prior to submission for publication of any paper, letter or any other publication, or thirty (30) fifteen (15) U.S business days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party the full details of the proposed publication or presentation in an electronic version (cd rom or email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation for an additional sixty (60) days in order to allow for actions to be taken to preserve rights for patent protection. (ii)The (ii) The publishing Party shall give reasonable consideration to any request by the other Party made within the periods mentioned in clause (i) of this Section 13.4 12.4 to modify the publication. (iii)The (iii) The publishing Party shall remove all Confidential Information of the other Party (but shall not remove jointly owned Study Data) before finalizing the publication. 13.5.Acknowledgement. 12.5 Acknowledgement. Each Party agrees to identify the other Party and acknowledge its support in any press release and any other publication or presentation of the results Study Data or Study Results of any Study.
View More
Publication. 13.1.Publicity. Unless otherwise required by Applicable Law (including regulations under any stock exchange on which either Party or its Affiliates is listed), neither Party shall make any public announcement concerning this Agreement or any Study (including any postings to www.clinicaltrials.gov. under Section 13.2) or otherwise communicate with any news media without the prior written consent of the other Party. Without limiting the previous sentence, to the extent a Party desires to make such... public announcement, such Party shall provide the other Party with a draft thereof at least seven (7) Business Days 12.1 On August 25, 2014 prior to the date on which such Party would like to make opening of the public announcement, unless such ten day prior notice is not possible New York Stock Exchange, Advaxis will issue a press release in order to comply with Applicable Laws (including regulations under any stock exchange on which either Party or its Affiliates is listed); further provided however, that, in such case such Party shall provide a form mutually agreed by the other Party with as much advance notice as reasonably practicable. 13.2.Registration. Sponsor Parties. 12.2 Advaxis will register each the Study with the Clinical Trials Registry located at www.clinicaltrials.gov as required by Applicable Law. 24 13.3.Publications. Sponsor shall have and is committed to timely publication of the first right results following Study Completion, after taking appropriate action to secure Intellectual Property Rights (if any) arising from the Study. The publication of the results of the Study will be in accordance with the Protocol. Merck agrees not to publish the results of any Study Results subject involving the Advaxis Compound prior to Section 13.4 and the timely publication of the Study results by Advaxis. 12.3 Advaxis shall use commercially reasonable efforts to publish or present scientific papers regarding dealing with the Study Plan and Study Results Collaboration Program in accordance with accepted scientific practice. Regeneron agrees not to publish Study Results for any Study prior to the timely publication of the Study Results from such Study by Sponsor. 13.4.Review. 12.4 The Parties agree that prior to submission of any Study Data the results of the Collaboration Program for publication or presentation or any other dissemination of any such results, results including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to be published or presented according to the following procedure: (i)At least forty-five (45) days prior to submission for publication of any paper, letter or any other publication, or thirty (30) days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party the full details of the proposed publication or presentation in an electronic version (cd rom (cd-rom or email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation for an additional sixty (60) ninety (90) days in order to allow for actions to be taken to preserve rights for patent protection. (ii)The publishing Party shall give reasonable consideration to any request by the other Party made within the periods mentioned in clause (i) of this Section 13.4 above to modify the publication. (iii)The publishing Party shall remove all Confidential Information of the other Party (but shall not remove jointly owned Study Data) before finalizing the publication. 13.5.Acknowledgement. Certain portions of this document have been marked "[C.I. ]" to indicate that confidential treatment has been requested for such confidential information. The confidential portions have been omitted and submitted separately with the Securities and Exchange Commission. 12.5 Each Party agrees to identify the other Party and acknowledge its support in any press release and any other publication or presentation of the results of any the Study.
View More
Found in
Advaxis, Inc. contract
Publication. a) Part of the University's mission is to publish and disseminate research results developed under sponsored research projects. Consistent with this Agreement, University, its Principal Investigator and other University employees and/or students have the first right to disseminate or publish the results of the Research in accordance with this Section 6. After reasonable inquiry by Sponsor, Principal Investigator or other University employees and/or students choose not to disseminate or publish r...esults of the Research, Sponsor shall have the right to publish results of the Research. The University shall provide the Sponsor with a copy of any proposed publication [**] in advance of submission or presentation to third parties. The Sponsor shall determine whether any of its Confidential Information is included in the proposed publication. The Sponsor may reasonably require that any of its Confidential Information be removed from the proposed publication. The Sponsor may reasonably require that publication be delayed to permit the filing of patent applications. The Sponsor shall make such determinations within [**] of receipt of the proposed publication. Publication shall not be delayed more than [**] after receipt of the proposed publication by Sponsor. The Sponsor at its election shall be entitled to receive an acknowledgment of its sponsorship of the Research in any such publication. 3 b) The University shall have the final authority to determine the scope and content of any publications or presentations made by its students and employees in accordance with the conditions and limitations of this section.
View More
View Variations (2)
Found in
ARVINAS, INC. contract
Publication. a) (a) Part of the University's UNIVERSITY's mission is to publish and disseminate research results developed under sponsored research projects. Consistent with this Agreement, University, its Principal Investigator AGREEMENT, UNIVERSITY, PRINCIPAL INVESTIGATOR and other University UNIVERSITY employees and/or students have the first right to may disseminate or publish the results of the Research RESEARCH in accordance with this Section 6. After reasonable inquiry by Sponsor, Principal Investigat...or the AGREEMENT. Should UNIVERSITY, PRINCIPAL INVESTIGATOR or any other University employees UNIVERSITY employee and/or students choose not student desire to disseminate disclose publicly or publish to third parties, in writing or oral presentation, the results of the Research, Sponsor RESEARCH or any INVENTION, UNIVERSITY shall have the right to publish results 3 notify SPONSOR in writing of its intention at least [***] before such disclosure. YALE shall include with such notice a written description of the Research. The University shall provide oral presentation, or in the Sponsor with case of a copy manuscript or other proposed written disclosure, a current draft of any proposed publication [**] such written disclosure (provided that a final version is provided to SPONSOR at least [***] in advance of submission or presentation to third parties. publication). The Sponsor SPONSOR shall determine whether any of its Confidential Information CONFIDENTIAL INFORMATION is included in the proposed publication. The Sponsor SPONSOR may reasonably require that any of its Confidential Information CONFIDENTIAL INFORMATION be removed from the proposed publication. The Sponsor SPONSOR may request that UNIVERSITY file a patent application, copyright or other filing related to such INVENTION, and the SPONSOR may reasonably require that publication be delayed to permit the filing of patent applications. The Sponsor SPONSOR shall make such determinations within [**] [***] of receipt of the UNIVERSITY's notice, or within [***] of receipt of a final version of a proposed publication. written publication, if later. Publication shall not be delayed more than [**] [***] after receipt of the proposed publication, or final version, by the SPONSOR. If UNIVERSITY desires to disseminate, publish or publicize the results of RESEARCH or any INVENTION that result from VISITING SCIENTIST's activities and that is not patentable, and the SPONSOR objects to such proposed disclosure within the time period specified above, UNIVERSITY and SPONSOR will negotiate in good faith to determine whether the proposed disclosure can be modified or delayed, consistent with the objectives of each party. In no event shall YALE be prohibited from proceeding with any such publication by Sponsor. for more than a total of [***] calendar days. VISITING SCIENTIST may publish or publicize the results of RESEARCH that result from VISITING SCIENTIST's activities only with the prior written permission of the HOSTING FACULTY MEMBER. (b) The Sponsor SPONSOR at its election shall be entitled to receive an acknowledgment of its sponsorship of the Research RESEARCH in any such publication. 3 b) (c) The University UNIVERSITY shall have the final authority to determine the scope and content of any publications or presentations made by its students and employees in accordance with the conditions and limitations of this section.
View More
Found in
NextCure, Inc. contract
Publication. a) (a) Part of the University's mission is to publish and disseminate research results developed under sponsored research projects. Consistent with this Agreement, University, its the Principal Investigator and other University employees and/or students have the first right to may disseminate or publish the results of the Research in accordance with this Section 6. After reasonable inquiry without prior approval by Sponsor, Principal Investigator or other University employees and/or students cho...ose not to disseminate or publish results of the Research, Sponsor shall have the right to publish results of the Research. Sponsor. The University shall provide the Sponsor with a copy of any proposed publication [**] 45 days in advance of submission or presentation to third parties. The Sponsor shall determine whether any of its Confidential Information is included in the proposed publication. The Sponsor may reasonably require that any of its Confidential Information be removed from the proposed publication. The Sponsor may reasonably require that submission of the proposed publication to third parties and publication be W I delayed to permit the filing of patent applications. The Sponsor shall make such determinations within [**] forty-five (45) days of receipt of the proposed publication. Publication Submission of the proposed publication shall not be delayed more than [**] ninety (90) days after receipt of the proposed publication by the Sponsor. The Sponsor at its election shall be entitled to receive an acknowledgment of its sponsorship of the Research in any such publication. 3 b) 4 (b) The University shall have the final authority to determine the scope and content of any publications or presentations made by its students and employees in accordance with the conditions and limitations of this section.
View More
Found in
Inozyme Pharma, Inc. contract
Publication. The parties agree to work cooperatively to publish the results of each Clinical Study in a joint paper in an appropriate peer reviewed journal. The initial publication and any public disclosures (e.g., presentations, abstracts, etc.) of the results of the Clinical Study will require the approval of both parties. The CSOG will approve senior and first authorship on the initial joint publication of the results from each Clinical Study. The parties agree to give appropriate recognition for all scie...ntific or other contributions in any publication or presentation relating to a Clinical Study. 10.2 Separate Publications. Notwithstanding Section 10.1, if the parties are unable to publish a joint paper within [***] from completion of a Clinical Study, either party may publish or present the results of that Clinical Study without the consent of the other party subject to the following conditions: a party that wishes to publish or present separately will submit the abstract or manuscript of any proposed manuscript publication or any other public disclosure to the other party at least [***] calendar days before public disclosure, and the other party shall have the right to review and comment upon the proposed public disclosure in order to protect its Confidential Information and the patentability of any inventions disclosed therein. Upon the request of the party receiving such proposed publication, the public disclosure shall be delayed up to [***] additional calendar days to enable the other party to secure adequate intellectual property protection of any patentable subject matter contained therein that would otherwise be affected by the publication and to ensure that no Confidential Information of the non-publishing party is disclosed by such publication. Any such separate publication or presentation shall give appropriate credit to the other party including crediting the contributions and interpretations of the other party. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 19 10.3 Notice and Review. Each party agrees to furnish the other with copies of any proposed oral, written, graphic, or electronic public disclosures prior to submission for publication or presentation. Each party may review these disclosures for a period not to exceed [***] days to ensure that its Confidential Information is not improperly disclosed and may require the removal of its Confidential Information (excluding Study Data). In order to fully protect the intellectual property rights of both parties, any contemplated publication or other public disclosure containing the details of any intellectual property, whether or not patentable, copyrightable or other protectable, may be withheld for an additional period of [***] days or until a patent application or other form of intellectual property protection is filed thereon, whichever is first in time.
View More
View Variations (2)
Found in
Juno Therapeutics, Inc. contract
Publication. The parties agree to work cooperatively to publish the results of each Clinical Study Collaboration Project in a joint paper in an appropriate peer reviewed journal. The initial publication and any public disclosures (e.g., presentations, abstracts, etc.) of the results of the Clinical Study Collaboration Project will require the approval of both parties. The CSOG COG will approve senior and first authorship on the initial joint publication of the results from each Clinical Study. Collaboration ...Project. The parties agree to give appropriate recognition for all scientific or other contributions in any publication or presentation relating to a Clinical Study. Collaboration Project. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. -16- 10.2 Separate Publications. Publication. Notwithstanding Section 10.1, if the parties are unable to publish a joint paper within [***] from completion of a Clinical Study, Collaboration Project, either party may publish or present the results of that Clinical Study Collaboration Project without the consent of the other party subject to the following conditions: a party that wishes to publish or present separately will submit the abstract or manuscript of any proposed manuscript publication or any other public disclosure to the other party at least [***] calendar days before public disclosure, and the other party shall have the right to review and comment upon the proposed public disclosure in order to protect its Confidential Information and the patentability of any inventions disclosed therein. Upon the request of the party receiving such proposed publication, the public disclosure shall be delayed up to [***] additional calendar days [***] to enable the other party to secure adequate intellectual property protection of any patentable subject matter contained therein that would otherwise be affected by the publication and to ensure that no Confidential Information of the non-publishing party is disclosed by such publication. Any such separate publication or presentation shall give appropriate credit to the other party including crediting the contributions and interpretations of the other party. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 19 10.3 Notice and Review. Each party agrees to furnish the other with copies of any proposed oral, written, graphic, or electronic public disclosures prior to submission for publication or presentation. Each party may review these disclosures for a period not to exceed [***] days to ensure that its Confidential Information is not improperly disclosed and may require the removal of its Confidential Information (excluding Study Data). In order to fully protect the intellectual property rights of both parties, any contemplated publication or other public disclosure containing the details of any intellectual property, whether or not patentable, copyrightable or other protectable, may be withheld for an additional period of [***] days or until a patent application or other form of intellectual property protection is filed thereon, whichever is first in time.
View More
Found in
Juno Therapeutics, Inc. contract
Publication. Either Party may, with the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed, carry out a "Publication Activity," including, but not limited to, publishing or presenting at any symposia, national, international or regional professional meeting or in any journal, thesis, dissertation, newspaper or otherwise of its own choosing, the findings, methods and results derived from work carried out under this Agreement. The Party having received such propos...ed publication shall have thirty (30) days to identify any Confidential Information or potentially patentable subject matter that needs protection and to provide written comments to the Publishing Party. 16 2.If no objection is made to the proposed publication or presentation within the stipulated time, the Publishing Party shall be free to proceed with the publication or presentation. In accordance with scientific custom, each Party shall ensure that due acknowledgement and credit is given to the other Party and its relevant staff members who contributed towards the work and the development of any IP that are the subject of the publication or presentation.
View More
View Variation
Found in
PharmaCyte Biotech, Inc. contract
Publication. Either Party may, with the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed, withheld, carry out a an "Publication Activity," including, Activity" including but not limited to, publishing or presenting at any symposia, national, international or regional professional meeting or in any journal, thesis, dissertation, newspaper or otherwise of its own choosing, the findings, methods and results derived from work carried out under this Agreement. Agre...ement.1.The Publishing Party intending to carry out a Publication Activity shall provide the other Party any such proposed publication or presentation in advance of the submission of such proposed activity to a journal, editor, or other third party. The Party having received such proposed publication shall have thirty (30) days to identify any Confidential Information or potentially patentable subject matter matters that needs need protection and to provide written comments to the Publishing Party. 16 2.If no objection is made to the proposed publication or presentation within the stipulated time, the Publishing Party shall be free to proceed with the publication or presentation. In accordance with scientific custom, each Party shall ensure that due acknowledgement and credit is given to the other Party and its relevant staff members who contributed towards the work and the development of any IP that are the subject of the publication, presentation, etc. in question. {00195092:} Licensing Agreement Notarization Page 3.Confidential Information identified by the non-publishing Party shall be deleted from the proposed publication or presentation unless the non-publishing Party agrees that the Confidential Information is not Intellectual Property and potentially patentable information, as set forth in Section 5 above.4.In the event that the non-publishing Party objects to any such publication or presentation on the basis that the same would disclose patentable information, the Publishing Party agrees to either change the presentation or publication or to delay as necessary up to a maximum of thirty (30) days to allow for one or both of the Parties to file any relevant patent applications with respect to the patentable subject matter contained in the proposed publication or presentation.
View More
Found in
PharmaCyte Biotech, Inc. contract